Literature DB >> 16219881

Incidence of end-stage renal disease in patients with type 1 diabetes.

Patrik Finne1, Antti Reunanen, Svante Stenman, Per-Henrik Groop, Carola Grönhagen-Riska.   

Abstract

CONTEXT: End-stage renal disease (ESRD) is one of the most severe complications of type 1 diabetes. Yet, data on patients' risk of developing ESRD are sparse.
OBJECTIVES: To estimate the long-term risk of developing ESRD and to assess how age at diagnosis of diabetes, time period of diagnosis, and sex affect the risk. DESIGN, SETTING, AND PATIENTS: A cohort of all patients younger than 30 years diagnosed as having type 1 diabetes in Finland in 1965-1999 (n = 20,005) was identified from the Finnish Diabetes Register. The cohort was followed up from diagnosis of diabetes until development of ESRD (dialysis or kidney transplantation as identified from the Finnish Registry for Kidney Diseases), death, or end of follow-up on December 31, 2001. MAIN OUTCOME MEASURE: Cumulative incidence of ESRD, accounting for death as a competing risk.
RESULTS: The cohort was followed up for maximally 37 years, with a median of 16.7 years. During 346 851 person-years, 632 patients developed ESRD. The cumulative incidence of ESRD was 2.2% at 20 years and 7.8% at 30 years after diagnosis. The risk of developing ESRD was lowest in patients whose diagnosis occurred at younger than 5 years. The risk of ESRD was lower for patients diagnosed as having type 1 diabetes in later years. The risk did not differ significantly between sexes.
CONCLUSIONS: With regard to ESRD, the prognosis of type 1 diabetes has improved during the past 4 decades. Children diagnosed as having diabetes before age 5 years have the most favorable prognosis. Overall, incidence of ESRD appears to be lower than previously estimated.

Entities:  

Mesh:

Year:  2005        PMID: 16219881     DOI: 10.1001/jama.294.14.1782

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  77 in total

1.  Glycemic control in Iranian children with type 1 diabetes mellitus: effect of gender.

Authors:  Aria Setoodeh; Fereydoun Mostafavi; Tina Hedayat
Journal:  Indian J Pediatr       Date:  2011-12-03       Impact factor: 1.967

2.  Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.

Authors:  Ian H de Boer; Wanjie Sun; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Bernard Zinman
Journal:  N Engl J Med       Date:  2011-11-12       Impact factor: 91.245

3.  Trends in estimated kidney function: the FINRISK surveys.

Authors:  Auni Juutilainen; Helena Kastarinen; Riitta Antikainen; Markku Peltonen; Veikko Salomaa; Jaakko Tuomilehto; Pekka Jousilahti; Jouko Sundvall; Tiina Laatikainen; Mika Kastarinen
Journal:  Eur J Epidemiol       Date:  2012-04       Impact factor: 8.082

4.  Renal complications of childhood type 1 diabetes.

Authors:  Jean-Claude Carel; Claire Levy-Marchal
Journal:  BMJ       Date:  2008-03-18

5.  Infusion of autologous bone marrow derived mononuclear stem cells potentially reduces urinary markers in diabetic nephropathy.

Authors:  Abduzhappar Gaipov; Zhannat Taubaldiyeva; Manarbek Askarov; Zaiyrkhan Turebekov; Larisa Kozina; Askhat Myngbay; Olga Ulyanova; Saltanat Tuganbekova
Journal:  J Nephrol       Date:  2018-11-07       Impact factor: 3.902

Review 6.  Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics.

Authors:  Julie A D Van; James W Scholey; Ana Konvalinka
Journal:  J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 10.121

7.  Requisite models for strategic commissioning: the example of type 1 diabetes.

Authors:  Mara Airoldi; Gwyn Bevan; Alec Morton; Mónica Oliveira; Jenifer Smith
Journal:  Health Care Manag Sci       Date:  2008-06

8.  Comorbidities and survival of patients with type 1 diabetes on renal replacement therapy.

Authors:  J Helve; M Haapio; P-H Groop; C Grönhagen-Riska; P Finne
Journal:  Diabetologia       Date:  2011-04-05       Impact factor: 10.122

9.  Simulating lifetime outcomes associated with complications for people with type 1 diabetes.

Authors:  Tom W C Lung; Philip M Clarke; Alison J Hayes; Richard J Stevens; Andrew Farmer
Journal:  Pharmacoeconomics       Date:  2013-06       Impact factor: 4.981

10.  Insulin therapy versus cell-based therapy for type 1 diabetes mellitus: what lies ahead?

Authors:  Alvin C Powers
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.